S&P 500   4,005.31 (+0.06%)
DOW   32,522.89 (-0.12%)
QQQ   311.23 (+0.29%)
AAPL   160.21 (+0.58%)
MSFT   276.09 (+0.84%)
META   202.75 (+0.29%)
GOOGL   104.89 (-0.03%)
AMZN   100.07 (-0.54%)
TSLA   197.96 (+0.19%)
NVDA   269.07 (+2.70%)
NIO   9.42 (+1.62%)
BABA   85.22 (+1.82%)
AMD   96.81 (+0.92%)
T   18.56 (+0.11%)
F   11.89 (+1.45%)
MU   58.83 (+0.34%)
CGC   1.97 (+-0.01%)
GE   92.24 (+0.07%)
DIS   96.42 (-0.12%)
AMC   4.57 (+3.63%)
PFE   40.57 (-0.22%)
PYPL   75.78 (-1.23%)
NFLX   301.32 (-1.46%)
S&P 500   4,005.31 (+0.06%)
DOW   32,522.89 (-0.12%)
QQQ   311.23 (+0.29%)
AAPL   160.21 (+0.58%)
MSFT   276.09 (+0.84%)
META   202.75 (+0.29%)
GOOGL   104.89 (-0.03%)
AMZN   100.07 (-0.54%)
TSLA   197.96 (+0.19%)
NVDA   269.07 (+2.70%)
NIO   9.42 (+1.62%)
BABA   85.22 (+1.82%)
AMD   96.81 (+0.92%)
T   18.56 (+0.11%)
F   11.89 (+1.45%)
MU   58.83 (+0.34%)
CGC   1.97 (+-0.01%)
GE   92.24 (+0.07%)
DIS   96.42 (-0.12%)
AMC   4.57 (+3.63%)
PFE   40.57 (-0.22%)
PYPL   75.78 (-1.23%)
NFLX   301.32 (-1.46%)
S&P 500   4,005.31 (+0.06%)
DOW   32,522.89 (-0.12%)
QQQ   311.23 (+0.29%)
AAPL   160.21 (+0.58%)
MSFT   276.09 (+0.84%)
META   202.75 (+0.29%)
GOOGL   104.89 (-0.03%)
AMZN   100.07 (-0.54%)
TSLA   197.96 (+0.19%)
NVDA   269.07 (+2.70%)
NIO   9.42 (+1.62%)
BABA   85.22 (+1.82%)
AMD   96.81 (+0.92%)
T   18.56 (+0.11%)
F   11.89 (+1.45%)
MU   58.83 (+0.34%)
CGC   1.97 (+-0.01%)
GE   92.24 (+0.07%)
DIS   96.42 (-0.12%)
AMC   4.57 (+3.63%)
PFE   40.57 (-0.22%)
PYPL   75.78 (-1.23%)
NFLX   301.32 (-1.46%)
S&P 500   4,005.31 (+0.06%)
DOW   32,522.89 (-0.12%)
QQQ   311.23 (+0.29%)
AAPL   160.21 (+0.58%)
MSFT   276.09 (+0.84%)
META   202.75 (+0.29%)
GOOGL   104.89 (-0.03%)
AMZN   100.07 (-0.54%)
TSLA   197.96 (+0.19%)
NVDA   269.07 (+2.70%)
NIO   9.42 (+1.62%)
BABA   85.22 (+1.82%)
AMD   96.81 (+0.92%)
T   18.56 (+0.11%)
F   11.89 (+1.45%)
MU   58.83 (+0.34%)
CGC   1.97 (+-0.01%)
GE   92.24 (+0.07%)
DIS   96.42 (-0.12%)
AMC   4.57 (+3.63%)
PFE   40.57 (-0.22%)
PYPL   75.78 (-1.23%)
NFLX   301.32 (-1.46%)
OTCMKTS:EPGNY

Epigenomics - EPGNY Stock Forecast, Price & News

$2.39
0.00 (0.00%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.39
▼
$2.39
50-Day Range
$2.39
▼
$9.56
52-Week Range
$2.01
▼
$2.39
Volume
N/A
Average Volume
100 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

EPGNY stock logo

About Epigenomics (OTCMKTS:EPGNY) Stock

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Receive EPGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epigenomics and its competitors with MarketBeat's FREE daily newsletter.

EPGNY Stock News Headlines

March 20, 2023 | uk.finance.yahoo.com
Epigenomics AG: Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation Act
March 14, 2023 | benzinga.com
Sample Preparation in Genomics, Proteomics, and Epigenomics Global Market Report 2023: Increased R&D Spending in Developing Economies Boosts Sector
March 22, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
March 10, 2023 | uk.finance.yahoo.com
Epigenomics AG: Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)
February 21, 2023 | marketwatch.com
Personalized Medicine and Epigenomics Market Capitalizing on Market Growth: Essential Insights from Our Latest Research Report
January 27, 2023 | uk.finance.yahoo.com
Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski
January 27, 2023 | markets.businessinsider.com
EQS-News: Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski
December 23, 2022 | markets.businessinsider.com
EQS-News: Pareto Securities AS publishes buy recommendation for Epigenomics AG share
March 22, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
December 21, 2022 | markets.businessinsider.com
EQS-Adhoc: Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022
December 14, 2022 | markets.businessinsider.com
EQS-Adhoc: Epigenomics Releases Performance Data on Next Generation Test
December 14, 2022 | uk.finance.yahoo.com
Epigenomics Releases Performance Data on Next Generation Test
December 14, 2022 | markets.businessinsider.com
EQS-News: Epigenomics Releases Performance Data on Next Generation Test
December 14, 2022 | markets.businessinsider.com
EQS-News: Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test
September 19, 2022 | markets.businessinsider.com
EQS-Adhoc: Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs
September 19, 2022 | uk.finance.yahoo.com
Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test
September 19, 2022 | markets.businessinsider.com
EQS-News: Epigenomics Initiates prospective multi-center clinical trial for Next-Generation blood-based colorectal cancer test
September 9, 2022 | markets.businessinsider.com
DGAP-Adhoc: Epigenomics AG: Capital reduction planned at a ratio of 4 : 1
August 15, 2022 | uk.finance.yahoo.com
Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG
August 15, 2022 | markets.businessinsider.com
DGAP-News: Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG
August 10, 2022 | markets.businessinsider.com
DGAP-News: Epigenomics AG Reports Financial Results for the First Six Months of 2022
May 11, 2022 | uk.finance.yahoo.com
Epigenomics AG Reports Financial Results for the First Quarter of 2022
May 11, 2022 | markets.businessinsider.com
DGAP-News: Epigenomics AG Reports Financial Results for the First Quarter of 2022
March 30, 2022 | marketwatch.com
Global Personalized Medicine and Epigenomics Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028
March 24, 2022 | markets.businessinsider.com
DGAP-News: Epigenomics AG Reports Financial Results for Fiscal Year 2021
January 14, 2022 | nasdaq.com
EPGNY After-Hours Quotes
January 6, 2022 | nasdaq.com
EPGNY Real-Time Quotes
See More Headlines
Receive EPGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epigenomics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:EPGNY
CUSIP
N/A
CIK
N/A
Web
www.epigenomics.com
Phone
(493) 024-3450
Fax
N/A
Employees
32
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Gregory K. Hamilton (Age 52)
    CEO & Member of the Exec. Board
    Comp: $828.44k
  • Dr. Andrew A. Lukowiak Ph.D. (Age 50)
    Pres & Chief Scientific Officer
    Comp: $387.44k
  • Mr. Jens Ravens (Age 52)
    CFO & Member of Exec. Board
  • Frederic Hilke
    Investor Relations Officer
  • Dr. Noel Thomas Doheny
    Chief Exec. Officer of Epigenomics Inc.

Key Competitors

View All Competitors













EPGNY Stock - Frequently Asked Questions

How have EPGNY shares performed in 2023?

Epigenomics' stock was trading at $9.56 at the beginning of 2023. Since then, EPGNY stock has decreased by 75.0% and is now trading at $2.39.
View the best growth stocks for 2023 here.

What is Epigenomics' stock symbol?

Epigenomics trades on the OTCMKTS under the ticker symbol "EPGNY."

How do I buy shares of Epigenomics?

Shares of EPGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Epigenomics' stock price today?

One share of EPGNY stock can currently be purchased for approximately $2.39.

How can I contact Epigenomics?

Epigenomics' mailing address is Geneststrasse 5, Berlin, Berlin 10829. The official website for the company is www.epigenomics.com. The company can be reached via phone at (493) 024-3450.

This page (OTCMKTS:EPGNY) was last updated on 3/22/2023 by MarketBeat.com Staff